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The following case contains my comments 
and not those of Sandoz. My team submit-
ted the New Drug Application (NDA) for 
LAMIISIL®, terbinafine Oral for onycho-
mycosis, fungal infection of toenails and 
fingernails. We showed efficacy and safety 
in all six pivotal studies. The FDA granted 
approval for this indication in adults.
While working on new indications for 
LAMISIL®, I received a call from Dr. Jerry 
Shenep at St. Jude’s Hospital. A 2-year-
old boy was admitted to his hospital with 
periorbital cellulitis and fever. This child 
splashed his face with muddy water while 
playing in a puddle. Physical examination 
showed swelling, erythema, and tenderness 
of the left periorbital area. CT of the face 
revealed left preseptal cellulitis with left 
maxillary opacification. He received intra-
venous cefotaxime for a presumed bacterial 
cellulitis. The infection spread to the nose 
and throat and compromised the airway. 
A surgical biopsy specimen grew Pythium 
insidiosum, an invasive water mold, sensi-
tive only to itraconazole and terbinafine. 
Itraconazole did not slow progression of the 
disease. In vitro testing showed synergy of 
the two antifungal agents. Consequently, Dr. 
Shenep pleaded with me to provide terbin-
afine on compassionate use basis, because 
it was this child’s only hope. Progression 
of disease may result in cavernous sinus 
thrombosis, meningitis, and death.
Expanded access, also known as “com-
passionate use,” provides an investigational 
drug outside of a clinical trial to treat a 
patient with a serious or immediately life-
threatening disease or condition who has 
no comparable or satisfactory alternative 
treatment options. FDA has a Guidance 
Document on Expanded Access that 
explains the requirements (1).
I admired Dr. Shenep’s passion and per-
sistence and wanted to help, but we faced 
several issues. First, we had not conducted 
pediatric clinical trials with terbinafine. 
In addition, we did not have an expanded 
access protocol in place.
At this time, one case of human pythiosis 
was reported in North America (2), involv-
ing a child with a similar presentation to this 
child. Extensive surgical debridement was 
required to control the infection.
Pythium species other than insidiosum 
infect plants. In1884, pythiosis was reported 
in horses by an Indian veterinarian (3). He 
 recognized that inoculation of infected 
tissue could transmit disease to healthy 
animals. P. insidiosum is the only species 
that causes infection in horses, dogs, and 
rarely in humans. Infection spreads through 
breaks in the skin via contact with water 
that contains motile zoospores or hyphae. 
Depending on the entry site, infection can 
lead to cutaneous, vascular, ocular, gastro-
intestinal, or rarely systemic infection. A 
devastating disease, cure of invasive infec-
tions in humans usually requires surgical 
debridement. Successful therapy in animals 
has not been reported; consequently, horses 
with this infection usually are destroyed.
As of 1996, 28 cases of human pythiosis 
had been published. Twenty three patients 
came from Thailand, almost all had thalas-
semia (4).
In humans, the few reported cases involv-
ing Pythium include arterial infections and 
cellulitis. Virgile et al. reported the first case of 
P. insidiosum isolated from a human corneal 
ulcer (5). Since the organism is resistant to 
standard antifungal drugs, surgical excision 
is the treatment choice for corneal infection.
Fortunately, my boss, a pediatric infec-
tious diseases specialist agreed with me to 
help Dr. Shenep’s patient. He calculated this 
child needed a dose of 125 mg twice daily. 
My Senior CRA called our supply group 
and we shipped drug overnight. I wrote 
an expanded access protocol that covered 
this request to treat this child and informed 
FDA. At least, I could sleep at night knowing 
we tried to help this child. I had two young 
children and would have wanted someone 
to help them. A month went by. I called Dr. 
Shenep and inquired about the child’s pro-
gress? Miraculous to relate, he said “fine.” 
After 1 year of treatment with both anti-
fungals, the child only had a slight left facial 
droop. Dr. Shenep reported the case (6) and 
he and I became friends.
Dr. Shenep’s request for compassionate 
use LAMISIL® was important for several 
reasons: it showed that cure of invasive P. 
insidiosum could be achieved with com-
bination antifungal therapy; in addition, 
it was a “proof of concept” for expanded 
access. Sadly, Dr. Shenep passed away, 
but his good work carries on through the 
expanded access program. I thank him for 
his persistence and the lesson he taught me.
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